Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Cash from Operations (2020 - 2025)

Historic Cash from Operations for Cellebrite DI (CLBT) over the last 6 years, with Q4 2025 value amounting to $86.8 million.

  • Cellebrite DI's Cash from Operations rose 3159.76% to $86.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $173.5 million, marking a year-over-year increase of 3130.26%. This contributed to the annual value of $173.5 million for FY2025, which is 3130.26% up from last year.
  • As of Q4 2025, Cellebrite DI's Cash from Operations stood at $86.8 million, which was up 3159.76% from $33.3 million recorded in Q3 2025.
  • Cellebrite DI's Cash from Operations' 5-year high stood at $86.8 million during Q4 2025, with a 5-year trough of -$10.5 million in Q1 2022.
  • In the last 5 years, Cellebrite DI's Cash from Operations had a median value of $18.7 million in 2023 and averaged $23.2 million.
  • As far as peak fluctuations go, Cellebrite DI's Cash from Operations tumbled by 839758.06% in 2022, and later surged by 534784.17% in 2023.
  • Cellebrite DI's Cash from Operations (Quarter) stood at $29.8 million in 2021, then increased by 19.98% to $35.7 million in 2022, then rose by 22.62% to $43.8 million in 2023, then surged by 50.51% to $66.0 million in 2024, then surged by 31.6% to $86.8 million in 2025.
  • Its Cash from Operations was $86.8 million in Q4 2025, compared to $33.3 million in Q3 2025 and $32.6 million in Q2 2025.